The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 21, 2019

Filed:

Apr. 10, 2014
Applicant:

Techlab, Inc., Blacksburg, VA (US);

Inventors:

James Hunter Boone, Christianburg, VA (US);

David M. Lyerly, Radford, VA (US);

Tracy D. Wilkins, Riner, VA (US);

Robert J. Carman, Christianburg, VA (US);

Assignee:

TECHLAB, INC., Blacksburg, VA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); A61K 35/74 (2015.01); A61K 45/06 (2006.01); A61K 38/14 (2006.01); A61K 31/4164 (2006.01); A61K 31/7034 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56911 (2013.01); A61K 31/4164 (2013.01); A61K 31/7034 (2013.01); A61K 35/74 (2013.01); A61K 38/14 (2013.01); A61K 45/06 (2013.01); G01N 2333/33 (2013.01); G01N 2333/79 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract

disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases ofare treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence ofdisease is detected using a biomarker panel that includesantigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected ofdisease, if GDH is detected indicating the presence of, and then toxins A and/or B are detected to indicate toxigenicand support a diagnosis of-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.


Find Patent Forward Citations

Loading…